

31<sup>st</sup> October, 2023

To,  
**Bombay Stock Exchange Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai – 400001

Dear Sir

**Sub :**            **Outcome of the Board Meeting under Regulation 30 and 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.**

**BSE Code :**    531210

We would like to inform you that, the Board of Directors of the Company at their meeting held today i.e. 31<sup>st</sup> October, 2023 has, inter alia considered and approved Unaudited Financial Results (as per IND-AS) for the quarter and half year ended on 30th September, 2023.

Enclosed herewith a copy of the same along with a copy of Limited Review Report dated 31<sup>st</sup> October, 2023 received from Vora & Associates, Chartered Accountants, Statutory Auditors of the Company with respect to Unaudited Financial Results for the quarter and half year ended on 30th September, 2023.

The Meeting commenced at 3:30 PM and concluded at 5.00 p.m.

This is for your information and record.

Thanking you,

Yours faithfully,

**FOR COLINZ LABORATORIES LTD**

  
**DR. MANI L.S.**  
**Chairman of the Meeting and Authorized Director**  
**DIN: 00825886**



**Colinz Laboratories Limited**

**CIN NO- L24200MH1986PLC041128**

**Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA**

**E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com**

**Mobile : 9137392123**



**VORA & ASSOCIATES**  
**CHARTERED ACCOUNTANTS**

101-103, REWA CHAMBERS  
31, NEW MARINE LINES  
MUMBAI - 400 020. INDIA

91-99305 75933  
022-2200 5933 - 2200 5934  
www.cavoras.com  
office@cavoras.com  
cavoras@gmail.com

**Independent Auditor's Review Report on Unaudited Quarterly Financial Results**

To  
The Board of Directors,  
**COLINZ LABORATORIES LIMITED.**


We have reviewed the accompanying statement of unaudited financial results ('the Statement') of **COLINZ LABORATORIES LIMITED** ('the Company') for the half year ended 30<sup>th</sup> September, 2023 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

This statement, which is the responsibility of the Company's Management and has been approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34') prescribed u/s 133 of the Companies Act, 2013 ('the Act'), SEBI Circular CIR/CF/FAC/62/2016 dated 05/07/2016 (hereinafter referred to as the 'the SEBI Circular') and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.


We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Statements Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Act read with relevant Rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For VORA & ASSOCIATES  
CHARTERED ACCOUNTANTS  
(ICAI Firm Reg. No.: 111612W)

  
RONAK A. RAMBHIA  
PARTNER

(Membership No.: 140371)



UDIN: 23140371BGQWAF1045  
PLACE: MUMBAI  
DATED: October 31, 2023

## COLINZ LABORATORIES LIMITED.

(CIN NO : L24200MH1986PLC041128)

A-101, Pratik Industrial Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai - 400 078.

AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED " 30th SEPTEMBER, 2023"

"(Rs. In Lakhs)"

S. No.	Particulars	Un-Audited					Audited
		Quarter ended			Six Month Ended		Year Ended
		30-Sep-23	30-Jun-23	30-Sep-22	30-Sep-22	30-Sep-23	31-Mar-23
<b>PART - I</b>							
1	(a) Revenue from Operation	178.62	189.94	191.65	375.46	368.56	715.49
3	(b) Other Income	7.59	4.43	4.51	8.63	12.02	17.21
3	<b>Total Income from Operation</b>	<b>186.21</b>	<b>194.37</b>	<b>196.16</b>	<b>384.09</b>	<b>380.58</b>	<b>732.70</b>
4	<b>Expenses</b>						
	(a) Cost Of Material Consumed	15.72	17.24	27.96	46.37	32.96	61.78
	(b) Purchase of Stock in Trade	49.48	36.63	24.80	78.23	86.11	170.85
	(c) Change in Inventories Of Finished Goods and Work in Progress and Stock in Trade	(7.72)	6.10	12.73	(2.05)	(1.61)	(3.32)
	(d) Employee Benefit Expenses	80.09	78.97	76.95	155.69	159.05	303.43
	(e) Finance Cost	0.92	0.81	1.32	2.55	1.73	5.23
	(f) Depreciation & Amortisation Expenses	3.26	3.26	3.22	6.44	6.52	12.89
	(g) Other Expenses	28.39	35.99	32.52	65.92	64.38	121.86
	<b>Total Expenses</b>	<b>170.14</b>	<b>179.00</b>	<b>179.50</b>	<b>353.15</b>	<b>349.14</b>	<b>672.72</b>
5	<b>Profit /(Loss) Before exceptional items and tax ( 3-4)</b>	<b>16.07</b>	<b>15.37</b>	<b>16.66</b>	<b>30.94</b>	<b>31.44</b>	<b>59.98</b>
6	Exceptional items	-	-	-	-	-	-
7	<b>Profit /(Loss) before tax (5-6)</b>	<b>16.07</b>	<b>15.37</b>	<b>16.66</b>	<b>30.94</b>	<b>31.44</b>	<b>59.98</b>
8	Tax Expenses ( Provision for Taxation ) Current tax						
	i) Current Tax	3.75	3.25	5.00	8.25	7.00	15.80
	ii) Deffered Tax	-	-	-	-	-	-
	iii) Tax for earlier years	-	-	-	-	-	(1.56)
	iv) MAT Credit of Earlier years	-	-	-	-	-	-
9	<b>Profit /(Loss) for the period from continuing operations(7-8)</b>	<b>12.32</b>	<b>12.12</b>	<b>11.66</b>	<b>22.69</b>	<b>24.44</b>	<b>45.74</b>
10	<b>Profit /(Loss) for the period</b>	<b>12.32</b>	<b>12.12</b>	<b>11.66</b>	<b>22.69</b>	<b>24.44</b>	<b>45.74</b>
11	<b>Other Comprehensive Income ( Net of Tax)</b>						
	A) Item that will not be reclassified to Profit or Loss Account						
	i) Change in fair value of investment in Equity Instruments	3.42	11.40	10.05	4.00	14.82	(0.57)
12	<b>Total Comprehensive Income for the period (10+11) Comprising</b>	<b>15.74</b>	<b>23.52</b>	<b>21.71</b>	<b>26.69</b>	<b>39.26</b>	<b>45.17</b>
13	Earning per equity share ( for Continuing operation) (In Rs.)						
	i) Basic	0.49	0.48	0.46	0.90	0.97	1.82
	ii) Diluted	0.49	0.48	0.46	0.90	0.97	1.82



**Colinz Laboratories Limited**


CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Mobile : 9137392123

<b>STATEMENT OF ASSETS AND LIABILITIES</b>				
Particulars			30-Sep-23	31-Mar-2023
<b>Non-Current Assets</b>				
a) Property, Plants & Equipment			164.41	170.92
b) Capital Work-in progress			-	-
c) Intangible Assets			-	-
d) Financial Assets				
i) Investments			82.76	66.29
ii) Loans			-	-
iii) Other Financial Assets			-	-
e) Other Non Current Assets			4.45	2.34
<b>Total Non-Current Assets</b>			<b>251.62</b>	<b>239.55</b>
<b>Current Assets</b>				
a) Inventories			91.48	93.88
b) Financial Assets				
i) Trade Receivables			120.25	113.41
ii) Cash & Cash Equivalents			248.11	196.54
iii) Other Bank Balances			386.62	376.34
iv) Other Financial Assets			-	-
c) Other Current Assets			2.78	3.36
<b>Total Current Assets</b>			<b>849.24</b>	<b>783.53</b>
<b>TOTAL ASSETS</b>			<b>1100.86</b>	<b>1023.08</b>
<b>EQUITY AND LIABILITIES</b>				
<b>Equity</b>				
a) Equity Share Capital			251.91	251.91
b) Other Equity			601.27	562.01
<b>Total Equity</b>			<b>853.18</b>	<b>813.92</b>
<b>Liabilities</b>				
<b>Non-Current Liabilities</b>				
a) Deferred Tax Liabilities ( Net)			22.20	20.55
b) Other Non Current Liabilities			-	-
<b>Total Non-Current Liabilities</b>			<b>22.20</b>	<b>20.55</b>
<b>Current Liabilities</b>				
a) Financial Liabilities				
i) Borrowings			46.03	27.34
ii) Trade Payables			62.05	65.44
b) Other Current Liabilities			108.87	87.30
c) Current Provisions			8.53	8.53
<b>Total Current Liabilities</b>			<b>225.48</b>	<b>188.61</b>
<b>TOTAL EQUITY AND LIABILITIES</b>			<b>1100.86</b>	<b>1023.08</b>



**Colinz Laboratories Limited**

CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Mobile : 9137392123

# COLINZ LABORATORIES LTD.

CASH FLOW STATEMENT FOR THE YEAR ENDED 30-09-2023

Rs. In Lacs

	April 01, 2023 To Sept. 30, 2023	April 01, 2022 To March 31, 2023
<b>A) CASH FLOW FROM OPERATING ACTIVITIES:</b>		
Profit Before Taxation	31.44	59.98
Adjustments for:		
Depreciation/Impairment	6.52	12.89
Loss on sale of Assets	0.00	2.37
Interest Expense	1.73	5.23
Interest Income	(11.43)	(16.34)
Dividend Income	(0.60)	(0.87)
<b>Operating Profit Before Working Capital Changes</b>	<b>27.66</b>	<b>63.26</b>
<b>Adjustments for changes in working capital:</b>		
Increase / (Decrease) in Trade Payable	(3.39)	17.93
Increase / (Decrease) in Short Term Borrowings	18.69	(21.11)
Increase / (Decrease) in Current Provisions	0.00	(4.02)
Increase / (Decrease) in Other Current Liabilities	21.58	(2.34)
Increase / (Decrease) in Other Long Term Current Liabilities	0.00	(4.07)
(Increase) / Decrease in Trade Receivables	(6.85)	7.19
(Increase) / Decrease in Inventories	2.40	(1.35)
(Increase) / Decrease in Other Non Current Assets	0.00	(0.21)
(Increase) / Decrease in Other Current Assets	0.57	0.81
<b>Cash Generated / (Used In) from Operations</b>	<b>60.66</b>	<b>56.07</b>
Taxes Paid (Net)	(9.11)	(15.80)
<b>Net Cash generated from / (Used In) Operating Activities</b>	<b>51.55</b>	<b>40.29</b>
<b>B) CASH FLOW FROM INVESTING ACTIVITIES:</b>		
Purchase of Fixed Assets	0.00	0.00
Investments in shares & securities (Net)	0.00	0.00
Call Money Received (Shares)	0.00	0.00
Dividend Income	0.60	0.87
<b>Net Cash (Used In) Investing Activities</b>	<b>0.60</b>	<b>0.87</b>
<b>C) CASH FLOW FROM FINANCING ACTIVITIES:</b>		
Interest received	11.43	16.34
Interest Expense	(1.73)	(5.23)
<b>Net Cash (Used In) / generated from Financing Activities</b>	<b>9.69</b>	<b>11.11</b>
<b>Net increase in Cash and Cash Equivalents (A+B+C)</b>	<b>61.84</b>	<b>52.27</b>
Cash and Cash Equivalents as at the beginning of the year	572.89	520.62
Cash and Cash Equivalents as at the end of the year	634.73	572.89
<b>Cash and Cash Equivalents comprise of:</b>		
Cash in Hand	1.62	0.83
Balances with Scheduled Banks in:		
- Current Accounts	246.49	195.72
Other Bank Balances	386.62	376.34
	<b>634.73</b>	<b>572.89</b>


**Notes:**

1. The above cash flow statement has been prepared under the "Indirect Method" set out in Ind AS 7, "Cash Flow" issued by the Institute of Chartered Accountants of India.
2. Cash and cash equivalents represent cash & bank balances and Other Bank Balances
3. Previous Year's figures have been regrouped and rearranged, wherever necessary.

As per our report of even date attached

For VORA & ASSOCIATES  
CHARTERED ACCOUNTANTS  
(ICAI FRNo.: 111612W)

**RONAK A. RAMBHLIA**  
PARTNER  
(Membership No.: 140371)  
Place: Mumbai Date: 31-10-2023



For and on behalf of the Board of Directors

**DR. MANI L. S.**  
(Chairman of the Meeting & Authorised Director)  
(DIN NO : 00825886)



Date: 31-10-2023


## NOTES TO THE FINANCIAL RESULTS :-

- 1) The above financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meetings held on 31st Oct.,2023.
- 2) The above results of the Company has been audited by the Statutory Auditors and they have issued an unqualified audit opinoin on the same.
- 3) The Company is primarily engaged in the business of manufacturing Pharmaceutical Formulations and there is no other reportable segment.
- 4) Previous period figures have been regrouped/ rearranged / reclassified, wherever necessary.
- 5) In accordance with regulation 33 of the SEBI( Listing Obligations and Disclosure Requirements) Regulation,2015, The Audited Results for Quarter and period ended **30th September,2023** are available on the BSE website (URL: [www.bselindia.com](http://www.bselindia.com)) and the Company's website (URL: [www.findoc-cll.in](http://www.findoc-cll.in)).



Place : Mumbai  
Date : 31-10-2023

For and on behalf of the Board  
**COLINZ LABORATORIES LTD.**  
CIN NO : L24200MH1986PLC041128

  
Dr. MANI L. S.  
(Chairman of the Meeting & Authorised Director)  
(DIN NO : 00825886)



**Colinz Laboratories Limited**

CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : [colinzlabs@yahoo.com](mailto:colinzlabs@yahoo.com) / [colinzlabs@gmail.com](mailto:colinzlabs@gmail.com)

Mobile : 9137392123